LB Pharmaceuticals Inc Common Stock

NASDAQ:LBRX

Biotechnology

Healthcare
$40.06 -1.30%

-$0.39 today

Market cap
$1.30B
Beta
0.71
P/E (TTM)
-21.4
EPS (TTM)
-$1.39
52W Low $13.36High $33.47

Volume 0.36M

Average 0.23M

LBRX Gross Profit

Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.

LB Pharmaceuticals Inc Common StockNASDAQ: LBRX

Gross Profit · Q1 FY2026 · quarter ended Mar 2026

Gross profit turns negative

Q1 FY2026 gross profit was -$82K, compared with $0 a year earlier. Trailing-twelve-month gross profit was -$82K.

Context

  • Gross profit increased in 0 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly gross profit holds near -$82K or moves back toward the trailing-twelve-month quarterly average of -$20.5K.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$82K— QoQ
Last fiscal yearDec 2025
$0— YoY
LTMMar 2026
-$82K— YoY
Gross Profit past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Gross Profit history

USD · from the income statement

Latest · FY2025
0 USD
Year-over-year change
—

Gross Profit vs competitors

How LBRX compares with its peers on the latest reported figures

  • LBRX's LTM Mar 2026 gross profit of -$82K is the 5th highest of the 10 companies compared; the peer median is -$268K.
LBRX Competitors Peer median
Gross Profit for LBRX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ACADACADIA Pharmaceuticals Inc.LTM Sep 2026$780.68M -18.9%+24.7%64.9%
RAPPRapport Therapeutics, Inc. Common StockLTM Mar 2026$19M +2140.8%—95.0%
DFTXDefinium Therapeutics, Inc.LTM Sep 2026$0 ———
NERVMinerva Neurosciences, Inc.LTM Jun 2026$0 ———
LBRXLB Pharmaceuticals Inc Common StockLTM Mar 2026-$82K ———
GHRSGH Research PLCLTM Mar 2026-$268K ———
ANROAlto Neuroscience, Inc.LTM Mar 2026-$284K -67.1%——
MPLTMapLight Therapeutics, Inc.LTM Mar 2026-$574K -69.3%——
DNLIDenali Therapeutics Inc.LTM Jun 2026-$2.2M ——61.0%
NMRANeumora Therapeutics, Inc. Common StockLTM Mar 2026-$5.01M ———
SPTXSeaport Therapeutics, Inc. Common Stock—— ———
Peer median (excluding LBRX) -$268K-43.0%+24.7%64.9%

Competitors are the stored peer set for LBRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue0000
Cost of Revenue0000
Gross Profit0000
Gross Margin————
Research & Development1.35M7.85M51.17M16.74M
Selling, General & Admin1.46M3.53M13.66M13.66M
Operating Expenses2.81M11.38M64.83M30.4M
Depreciation & Amortization2K4K91K321K
EBITDA(12.19M)(1.45M)(63.01M)(24.88M)
EBITDA Margin————
Operating Income(2.81M)(11.38M)(64.83M)(30.4M)
Operating Margin————
Interest Income73K811K1.72M3.92M
Interest Expense2.15M4.83M00
Other Income / Expenses(11.54M)5.1M1.73M5.2M
Income Before Tax(14.35M)(6.27M)(63.1M)(25.2M)
Pre-Tax Margin————
Income Tax Expense1K1K1K1K
Net Income(14.35M)(6.28M)(63.1M)(25.21M)
Net Margin————
EPS (Basic)(4.05)(1.77)(17.83)(1.00)
EPS (Diluted)(4.05)(1.77)(17.83)(1.00)
Weighted Avg Shares3.54M3.54M3.54M25.3M
Weighted Avg Shares (Diluted)3.54M3.54M3.54M25.3M

LB Pharmaceuticals Inc Common Stock

NASDAQ:LBRX

Intrinsic Alpha fair value

Locked

Current Price

$40.06

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.